Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-11-03
DOI
10.3389/fimmu.2021.662223
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial
- (2021) Martin Kaul et al. CTS-Clinical and Translational Science
- Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies
- (2021) Katharine L Lewis et al. Journal of Personalized Medicine
- Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia
- (2020) David J. Kuter et al. BLOOD
- Pharmacodynamic analysis of BTK inhibition in patients with chronic lymphocytic leukemia treated with acalabrutinib
- (2020) Anfal Alsadhan et al. CLINICAL CANCER RESEARCH
- Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
- (2020) Daniela Angst et al. JOURNAL OF MEDICINAL CHEMISTRY
- Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition
- (2020) Albert Liclican et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms
- (2020) Daniel P. Duarte et al. Nature Communications
- Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study)
- (2020) Stanley Cohen et al. Arthritis & Rheumatology
- Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
- (2020) Krista Isaac et al. Cancer Management and Research
- Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis
- (2020) Sebastian Torke et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Current State of Knowledge on Primary Sjögren’s Syndrome, an Autoimmune Exocrinopathy
- (2020) Dorian Parisis et al. Journal of Clinical Medicine
- Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects
- (2020) H. Yesid Estupiñán et al. Blood Advances
- Kinase inhibition in autoimmunity and inflammation
- (2020) Ali A. Zarrin et al. NATURE REVIEWS DRUG DISCOVERY
- Cardiotoxicity of Novel Targeted Hematological Therapies
- (2020) Valentina Giudice et al. Life-Basel
- Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)
- (2019) Scott H. Watterson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Management of adverse effects/toxicity of ibrutinib
- (2019) Semra Paydas CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis
- (2019) Chufeng Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models
- (2019) Philipp Haselmayer et al. JOURNAL OF IMMUNOLOGY
- Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
- (2019) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study
- (2019) Edmund K. Waller et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Prevalence of BTK and PLCG2 mutations in a real‑life CLL cohort still on ibrutinib after three years: a FILO group study
- (2019) Anne Quinquenel et al. BLOOD
- Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
- (2019) Yunhang Guo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Multiple Functions of B Cells in the Pathogenesis of Systemic Lupus Erythematosus
- (2019) Kongyang Ma et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nuclear localization of the tyrosine kinase BMX mediates VEGFR2 expression
- (2019) Tingting Liu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Ibrutinib in CLL/SLL: From bench to bedside (Review)
- (2019) Fuming Zi et al. ONCOLOGY REPORTS
- Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor
- (2019) Xuejun Zhang et al. ACS Medicinal Chemistry Letters
- The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)
- (2018) Jun Chen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development
- (2018) James J. Crawford et al. JOURNAL OF MEDICINAL CHEMISTRY
- Reassessing B cell contributions in multiple sclerosis
- (2018) Rui Li et al. NATURE IMMUNOLOGY
- The Src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases
- (2018) Neel H. Shah et al. CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
- (2017) Tjeerd Barf et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care
- (2017) Kathleen M. Gillooly et al. PLoS One
- Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease
- (2017) Odilia B. J. Corneth et al. Arthritis & Rheumatology
- Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
- (2016) A. R. Mato et al. BLOOD
- Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers
- (2016) Scott H. Watterson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bruton's Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice but Fails to Block Immune Complex-Mediated Inflammatory Arthritis
- (2016) Lindsay E. Nyhoff et al. Arthritis & Rheumatology
- THU0068 Preclinical Characterization of PRN1008, a Novel Reversible Covalent Inhibitor of BTK that Shows Efficacy in a RAT Model of Collagen-Induced Arthritis
- (2015) R.J. Hill et al. ANNALS OF THE RHEUMATIC DISEASES
- Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study
- (2015) A.-P. Trouvin et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling
- (2015) Tanja Holopainen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune response in pemphigus and beyond: progresses and emerging concepts
- (2015) Giovanni Di Zenzo et al. Seminars in Immunopathology
- 2015 ACR/ARHP Annual Meeting Abstract Supplement
- (2015) Arthritis & Rheumatology
- FRI0364 Hm71224, A Novel BTK Inhibitor Demonstrates Potent Activities in Rodent Models of Arthritis
- (2014) S.Y. Jang et al. ANNALS OF THE RHEUMATIC DISEASES
- Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
- (2014) M. Levade et al. BLOOD
- Update on B-cell targeted therapies for systemic lupus erythematosus
- (2014) Chi Chiu Mok EXPERT OPINION ON BIOLOGICAL THERAPY
- Btk Regulates B Cell Receptor-Mediated Antigen Processing and Presentation by Controlling Actin Cytoskeleton Dynamics in B Cells
- (2014) S. Sharma et al. JOURNAL OF IMMUNOLOGY
- CXCL13, CCL21, and CXCL12 Expression in Salivary Glands of Patients with Sjogren's Syndrome and MALT Lymphoma: Association with Reactive and Malignant Areas of Lymphoid Organization
- (2014) F. Barone et al. JOURNAL OF IMMUNOLOGY
- The Phosphoinositide 3-Kinase-Dependent Activation of Btk Is Required for Optimal Eicosanoid Production and Generation of Reactive Oxygen Species in Antigen-Stimulated Mast Cells
- (2014) H. S. Kuehn et al. JOURNAL OF IMMUNOLOGY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
- (2014) Glynn Dennis et al. ARTHRITIS RESEARCH & THERAPY
- B-Cell Targeted Therapies in Systemic Lupus Erythematosus
- (2013) Philip R. Harvey et al. BIODRUGS
- B-cell-targeted therapies in systemic lupus erythematosus
- (2013) Vera Sau-Fong Chan et al. Cellular & Molecular Immunology
- The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment
- (2013) G. Cambridge et al. JOURNAL OF AUTOIMMUNITY
- Brutonˈs tyrosine kinase-an integral protein of B cell development that also has an essential role in the innate immune system
- (2013) Gabriela López-Herrera et al. JOURNAL OF LEUKOCYTE BIOLOGY
- The Pathogenesis of Lupus Nephritis
- (2013) M. Lech et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Novel autoantibodies in Sjogren's syndrome
- (2012) Long Shen et al. CLINICAL IMMUNOLOGY
- BMX and Its Role in Inflammation, Cardiovascular Disease, and Cancer
- (2012) Bruno Cenni et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor
- (2011) Donald MacGlashan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- The Tyrosine Kinase BMX Is an Essential Mediator of Inflammatory Arthritis in a Kinase-Independent Manner
- (2011) M. Gottar-Guillier et al. JOURNAL OF IMMUNOLOGY
- A Balance of Bruton's Tyrosine Kinase and SHIP Activation Regulates B Cell Receptor Cluster Formation by Controlling Actin Remodeling
- (2011) C. Liu et al. JOURNAL OF IMMUNOLOGY
- Long-lived autoreactive plasma cells drive persistent autoimmune inflammation
- (2011) Falk Hiepe et al. Nature Reviews Rheumatology
- Chemokine saliva levels in patients with primary Sjogren's syndrome, associated Sjogren's syndrome, pre-clinical Sjogren's syndrome and systemic autoimmune diseases
- (2011) G. Hernandez-Molina et al. RHEUMATOLOGY
- Btk-dependent Rac activation and actin rearrangement following Fc RI aggregation promotes enhanced chemotactic responses of mast cells
- (2010) H. S. Kuehn et al. JOURNAL OF CELL SCIENCE
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials
- (2010) Young Ho Lee et al. RHEUMATOLOGY INTERNATIONAL
- The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo
- (2009) M.-P. Gratacap et al. BLOOD
- Early signal protein expression profiles in basophils: a population study
- (2009) Susan Ishmael et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Pathological Expression of CXCL12 at the Blood-Brain Barrier Correlates with Severity of Multiple Sclerosis
- (2008) Erin E. McCandless et al. AMERICAN JOURNAL OF PATHOLOGY
- Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals
- (2008) Masahiro Shinohara et al. CELL
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started